WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

A lot is riding on the case for Novartis, as Entresto is its top-selling product, contributing more than $5.6 billion in the first nine months of the year – 19% of its total revenues for the ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

Panelists discuss how black box warnings on IV iron products, particularly regarding hypersensitivity reactions, influence their risk assessment, patient selection, monitoring protocols ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 2,146.62 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Job Title Sort ascending Business Location Site Date Posted Therapeutic Area Partner Regular (Sales), Full time Innovative Medicines Utd.Arab Emir. Dubai Feb 03, 2025 Senior Specialist, IT Information ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

In December, Indonesia's total stainless steel exports decreased by approximately 7.18% MoM, with mixed performance in exports to major global consumer countries [SMM Analysis]. Stainless Steel ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent ... exclusivities and other restrictions. The branded reference product, Xifaxan, is an oral antibacterial indicated ...